254 related articles for article (PubMed ID: 26876154)
1. Pyruvate Kinase M2 Activates mTORC1 by Phosphorylating AKT1S1.
He CL; Bian YY; Xue Y; Liu ZX; Zhou KQ; Yao CF; Lin Y; Zou HF; Luo FX; Qu YY; Zhao JY; Ye ML; Zhao SM; Xu W
Sci Rep; 2016 Feb; 6():21524. PubMed ID: 26876154
[TBL] [Abstract][Full Text] [Related]
2. Prognostic and therapeutic implications of mTORC1 and Rictor expression in human breast cancer.
Wazir U; Newbold RF; Jiang WG; Sharma AK; Mokbel K
Oncol Rep; 2013 May; 29(5):1969-74. PubMed ID: 23503572
[TBL] [Abstract][Full Text] [Related]
3. Mutant p53 and mTOR/PKM2 regulation in cancer cells.
Dando I; Cordani M; Donadelli M
IUBMB Life; 2016 Sep; 68(9):722-6. PubMed ID: 27385486
[TBL] [Abstract][Full Text] [Related]
4. mLST8 Promotes mTOR-Mediated Tumor Progression.
Kakumoto K; Ikeda J; Okada M; Morii E; Oneyama C
PLoS One; 2015; 10(4):e0119015. PubMed ID: 25906254
[TBL] [Abstract][Full Text] [Related]
5. Fisetin regulates obesity by targeting mTORC1 signaling.
Jung CH; Kim H; Ahn J; Jeon TI; Lee DH; Ha TY
J Nutr Biochem; 2013 Aug; 24(8):1547-54. PubMed ID: 23517912
[TBL] [Abstract][Full Text] [Related]
6. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
[TBL] [Abstract][Full Text] [Related]
7. Down-regulation of PKM2 decreases FASN expression in bladder cancer cells through AKT/mTOR/SREBP-1c axis.
Tao T; Su Q; Xu S; Deng J; Zhou S; Zhuang Y; Huang Y; He C; He S; Peng M; Hocher B; Yang X
J Cell Physiol; 2019 Mar; 234(3):3088-3104. PubMed ID: 30221356
[TBL] [Abstract][Full Text] [Related]
8. Pyruvate kinase isoform M2 (PKM2) participates in multiple myeloma cell proliferation, adhesion and chemoresistance.
He Y; Wang Y; Liu H; Xu X; He S; Tang J; Huang Y; Miao X; Wu Y; Wang Q; Cheng C
Leuk Res; 2015 Dec; 39(12):1428-36. PubMed ID: 26453405
[TBL] [Abstract][Full Text] [Related]
9. Cucurbitacin E Induces Autophagy via Downregulating mTORC1 Signaling and Upregulating AMPK Activity.
Zha QB; Zhang XY; Lin QR; Xu LH; Zhao GX; Pan H; Zhou D; Ouyang DY; Liu ZH; He XH
PLoS One; 2015; 10(5):e0124355. PubMed ID: 25970614
[TBL] [Abstract][Full Text] [Related]
10. Improvement of mTORC1-driven overproduction of apoB-containing triacylglyceride-rich lipoproteins by short-chain fatty acids, 4-phenylbutyric acid and (R)-α-lipoic acid, in human hepatocellular carcinoma cells.
Roberts JL; He B; Erickson A; Moreau R
Biochim Biophys Acta; 2016 Mar; 1861(3):166-76. PubMed ID: 26680362
[TBL] [Abstract][Full Text] [Related]
11. Steady-state kinetic and inhibition studies of the mammalian target of rapamycin (mTOR) kinase domain and mTOR complexes.
Tao Z; Barker J; Shi SD; Gehring M; Sun S
Biochemistry; 2010 Oct; 49(39):8488-98. PubMed ID: 20804212
[TBL] [Abstract][Full Text] [Related]
12. Pyruvate kinase M2 interacts with nuclear sterol regulatory element-binding protein 1a and thereby activates lipogenesis and cell proliferation in hepatocellular carcinoma.
Zhao X; Zhao L; Yang H; Li J; Min X; Yang F; Liu J; Huang G
J Biol Chem; 2018 Apr; 293(17):6623-6634. PubMed ID: 29514980
[TBL] [Abstract][Full Text] [Related]
13. Aschantin targeting on the kinase domain of mammalian target of rapamycin suppresses epidermal growth factor-induced neoplastic cell transformation.
Lee CJ; Jang JH; Lee JY; Lee MH; Li Y; Ryu HW; Choi KI; Dong Z; Lee HS; Oh SR; Surh YJ; Cho YY
Carcinogenesis; 2015 Oct; 36(10):1223-34. PubMed ID: 26243309
[TBL] [Abstract][Full Text] [Related]
14. Human cytomegalovirus infection alters the substrate specificities and rapamycin sensitivities of raptor- and rictor-containing complexes.
Kudchodkar SB; Yu Y; Maguire TG; Alwine JC
Proc Natl Acad Sci U S A; 2006 Sep; 103(38):14182-7. PubMed ID: 16959881
[TBL] [Abstract][Full Text] [Related]
15. Role of PRAS40 in Akt and mTOR signaling in health and disease.
Wiza C; Nascimento EB; Ouwens DM
Am J Physiol Endocrinol Metab; 2012 Jun; 302(12):E1453-60. PubMed ID: 22354785
[TBL] [Abstract][Full Text] [Related]
16. Leucine facilitates the insulin-stimulated glucose uptake and insulin signaling in skeletal muscle cells: involving mTORC1 and mTORC2.
Liu H; Liu R; Xiong Y; Li X; Wang X; Ma Y; Guo H; Hao L; Yao P; Liu L; Wang D; Yang X
Amino Acids; 2014 Aug; 46(8):1971-9. PubMed ID: 24806638
[TBL] [Abstract][Full Text] [Related]
17. PKM2 promotes cell migration and inhibits autophagy by mediating PI3K/AKT activation and contributes to the malignant development of gastric cancer.
Wang C; Jiang J; Ji J; Cai Q; Chen X; Yu Y; Zhu Z; Zhang J
Sci Rep; 2017 Jun; 7(1):2886. PubMed ID: 28588255
[TBL] [Abstract][Full Text] [Related]
18. High prevalence of mTOR complex activity can be targeted using Torin2 in papillary thyroid carcinoma.
Ahmed M; Hussain AR; Bavi P; Ahmed SO; Al Sobhi SS; Al-Dayel F; Uddin S; Al-Kuraya KS
Carcinogenesis; 2014 Jul; 35(7):1564-72. PubMed ID: 24583924
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-451 regulates AMPK/mTORC1 signaling and fascin1 expression in HT-29 colorectal cancer.
Chen MB; Wei MX; Han JY; Wu XY; Li C; Wang J; Shen W; Lu PH
Cell Signal; 2014 Jan; 26(1):102-9. PubMed ID: 23899558
[TBL] [Abstract][Full Text] [Related]
20. mTORC1 upregulation via ERK-dependent gene expression change confers intrinsic resistance to MEK inhibitors in oncogenic KRas-mutant cancer cells.
Komatsu N; Fujita Y; Matsuda M; Aoki K
Oncogene; 2015 Nov; 34(45):5607-16. PubMed ID: 25703330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
